These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 17376209)

  • 1. Psoriasis treated with ursodeoxycholic acid: three case reports.
    Itoh S; Kono M; Akimoto T
    Clin Exp Dermatol; 2007 Jul; 32(4):398-400. PubMed ID: 17376209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.
    Lindor KD; Kowdley KV; Heathcote EJ; Harrison ME; Jorgensen R; Angulo P; Lymp JF; Burgart L; Colin P
    Hepatology; 2004 Mar; 39(3):770-8. PubMed ID: 14999696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study.
    Georgescu EF; Georgescu M
    J Gastrointestin Liver Dis; 2007 Mar; 16(1):39-46. PubMed ID: 17410287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis.
    Dufour JF; Oneta CM; Gonvers JJ; Bihl F; Cerny A; Cereda JM; Zala JF; Helbling B; Steuerwald M; Zimmermann A;
    Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1537-43. PubMed ID: 17162245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Negative trials in nonalcoholic steatohepatitis: why they happen and what they teach us.
    Clark JM; Brancati FL
    Hepatology; 2004 Mar; 39(3):602-3. PubMed ID: 14999677
    [No Abstract]   [Full Text] [Related]  

  • 6. Combined treatment with ursodeoxycholic acid and pioglitazone in a patient with NASH associated with type 2 diabetes and psoriasis.
    Itoh S; Kanazuka A; Akimoto T
    Dig Dis Sci; 2003 Nov; 48(11):2182-6. PubMed ID: 14705825
    [No Abstract]   [Full Text] [Related]  

  • 7. Ursodeoxycholic acid for nonalcoholic steatohepatitis.
    Wu SD; Li L; Wang JY
    Eur J Gastroenterol Hepatol; 2012 Nov; 24(11):1247-53. PubMed ID: 22864259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ursodeoxycholic acid reduces lipid peroxidation and mucin secretagogue activity in gallbladder bile of patients with cholesterol gallstones.
    Jüngst C; Sreejayan N; Zündt B; Müller I; Spelsberg FW; Hüttl TP; Kullak-Ublick GA; del Pozo R; Jüngst D; von Ritter C
    Eur J Clin Invest; 2008 Sep; 38(9):634-9. PubMed ID: 18837739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [UDCA in the treatment of nonalcoholic fatty liver disease].
    Grigor'eva IN
    Eksp Klin Gastroenterol; 2011; (9):125-31. PubMed ID: 22629789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid.
    Desmond CP; Wilson J; Bailey M; Clark D; Roberts SK
    Liver Int; 2007 Dec; 27(10):1402-8. PubMed ID: 18036103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy for nonalcoholic fatty liver disease.
    Moseley RH
    J Clin Gastroenterol; 2008 Apr; 42(4):332-5. PubMed ID: 18277910
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells.
    Arenas F; Hervias I; Uriz M; Joplin R; Prieto J; Medina JF
    J Clin Invest; 2008 Feb; 118(2):695-709. PubMed ID: 18188457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ursodeoxycholic acid treatment in isolated chronic graft-vs.-host disease of the liver.
    Arat M; Idilman R; Soydan EA; Soykan I; Erden E; Karayalçin S; Akan H
    Clin Transplant; 2005 Dec; 19(6):798-803. PubMed ID: 16313328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profiling of early primary biliary cirrhosis: possible insights into the mechanism of action of ursodeoxycholic acid.
    Chen L; Borozan I; Milkiewicz P; Sun J; Meng X; Coltescu C; Edwards AM; Ostrowski MA; Guindi M; Heathcote EJ; McGilvray ID
    Liver Int; 2008 Aug; 28(7):997-1010. PubMed ID: 18422935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of ursodeoxycholic acid alone and ursodeoxycholic acid plus low-dose acetylsalicylic acid on radiolucent gallstones.
    Tuncer I; Harman M; Mercan R; Oztürk M; Arslan I; Meral C; Türkdoğan MK
    Turk J Gastroenterol; 2003 Jun; 14(2):91-6. PubMed ID: 14614633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UDCA for NASH: end of the story?
    Haedrich M; Dufour JF
    J Hepatol; 2011 May; 54(5):856-8. PubMed ID: 21145815
    [No Abstract]   [Full Text] [Related]  

  • 17. [Use of ursodeoxycholic acid combined with silymarin in the treatment of chronic ethyl-toxic hepatopathy].
    Bettini R; Gorini M
    Clin Ter; 2002; 153(5):305-7. PubMed ID: 12510413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid.
    Assy N; Adams PC; Myers P; Simon V; Minuk GY; Wall W; Ghent CN
    Transplantation; 2007 Jun; 83(12):1571-6. PubMed ID: 17589339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-alcoholic steato-hepatitis.
    Chawla Y; Amrapurkar D
    Trop Gastroenterol; 2002; 23(4):186-8. PubMed ID: 12833707
    [No Abstract]   [Full Text] [Related]  

  • 20. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans.
    Marschall HU; Wagner M; Zollner G; Fickert P; Diczfalusy U; Gumhold J; Silbert D; Fuchsbichler A; Benthin L; Grundström R; Gustafsson U; Sahlin S; Einarsson C; Trauner M
    Gastroenterology; 2005 Aug; 129(2):476-85. PubMed ID: 16083704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.